Premium
Effect of high‐dose thymidine infusions in patients with mycosis fungoides
Author(s) -
Kufe D. W.,
Wick M. M.,
Moschella S.,
Major P.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19811001)48:7<1513::aid-cncr2820480705>3.0.co;2-q
Subject(s) - mycosis fungoides , medicine , thymidine , anorexia , lymphoma , dermatology , gastroenterology , pathology , in vitro , biology , biochemistry
Abstract The antitumor effect of thymidine has been demonstrated in patients with leukemia and lymphoma. This report summarizes the treatment of three patients with mycosis fungoides, a chronic T‐cell lymphoma. Four courses of thymidine (75 g/m 2 /day) were administered by continuous infusion for 4–7 days. Steady‐state serum thymidine levels were in the range of 1–3 mM. Associated toxicities were minimal and consisted of mild headache and anorexia. Myelosuppression was manifested by transient declines in the peripheral leukocyte count. One patient had extensive clearing of diffuse erythematous plaques on the trunk and extremities that persisted for over one month. A second patient had partial clearing of plaques that persisted for two weeks following therapy and a third patient had a minimal response with 25% reduction in lymphadenopathy and noduloulcerative lesions. These responses indicate the effectiveness of thymidine as a single agent in the treatment of mycosis fungoides.